Impaired thrombin-induced platelet activation and thrombus formation in mice lacking the Ca2+-dependent tyrosine kinase Pyk2

Blood

Volumn 121, Issue 4, 2013, Pages 648-657

  Canobbio, Ilaria ^a   Cipolla, Lina ^a   Consonni, Alessandra ^a   Momi, Stefania ^b   Guidetti, Gianni ^a   Oliviero, Barbara ^c   Falasca, Marco ^d   Okigaki, Mitsuhiko ^e   Balduini, Cesare ^a   Gresele, Paolo ^b   Torti, Mauro ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ADRENALIN; ALPHA2B BETA3 INTEGRIN; CALCIUM ION; COLLAGEN; CYTOSOLIC PHOSPHOLIPASE A2; FIBRINOGEN; FOCAL ADHESION KINASE 2; GLYCOPROTEIN VI; INTEGRIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEINASE ACTIVATED RECEPTOR 4; RECOMBINANT THROMBIN; THROMBIN; THROMBOXANE A2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY OCCLUSION; ARTERY THROMBOSIS; ARTICLE; BLEEDING TIME; BLOOD CLOTTING; CONTROLLED STUDY; ENZYME INHIBITION; EX VIVO STUDY; FEMORAL ARTERY THROMBOSIS; GRANULE CELL; IN VIVO STUDY; LOW DRUG DOSE; LUNG EMBOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TAIL; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; WILD TYPE;

EID: 84873029127     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-06-438762     Document Type: Article

References (47)

1. Avraham S, London R, Fu Y, et al. Identification and characterization of a novel related adhesion focal tyrosine kinase (RAFTK) from megakaryocytes and brain. J Biol Chem. 1995;270(46): 27742-27751.
2. Li J, Avraham H, Rogers RA, Raja S, Avraham S. Characterization of RAFTK, a novel focal adhesion kinase, and its integrin-dependent phosphorylation and activation in megakaryocytes. Blood. 1996;88(2):417-428.
3. Sasaki H, Nagura K, Ishino M, Tobioka H, Kotani K, Sasaki T. Cloning and characterization of cell adhesion kinase ß, a novel protein-tyrosine kinase of the focal adhesion kinase subfamily. J Biol Chem. 1995; 270(36):21206-21219.
4. Avraham H, Park SY, Schinkmann K, Avraham S. RAFTK/Pyk2-mediated cellular signalling. Cell Signal. 2000;12(3):123-133.
5. Ostergaard HL, Lysechko TL. Focal adhesion kinase-related protein tyrosine kinase Pyk2 in T-cell activation and function. Immunol Res. 2005;31(3):267-282.
6. Schaller MD. Cellular functions of FAK kinases: insight into molecular mechanisms and novel functions. J Cell Sci. 2010;123(Pt7):1007-1013.
7. Lev S, Moreno H, Martinez R, et al. Protein tyrosine kinase PYK2 involved in Ca2+induced regulation of ion channel and MAP kinase functions. Nature. 1995;376(6543):737-745.
8. Kohno T, Matsuda E, Sasaki H, Sasaki T Protein-tyrosine kinase CAKß/Pyk2 is activated by binding Ca2+ to FERM F2 a2 helix and thus forming its dimer. BiochemJ. 2008;410(3): 513-523.
9. Raja S, Avraham S, Avraham H. Tyrosine phosphorylation of the novel protein-tyrosine kinase RAFTK during an early phase of platelet activation by an integrin glycoprotein IIb-IIIa-independent mechanism. J Biol Chem. 1997;272(16):10941-10947.
10. Ohmori T, Yatomi Y, Asazuma N, Satoh K, Ozaki Y Involvement of proline-rich tyrosine kinase 2 in platelet activation: tyrosine phosphorylation mostly dependent on aIIbß3 integrin and protein kinase C, translocation to the cytoskeleton and association with Shc through Grb2. BiochemJ. 2000;347(Pt2):561-569.
11. Canobbio I, Lova P, Sinigaglia F, Balduini C, Torti M. Proline-rich tyrosine kinase 2 and focal adhesion kinase are involved in different phases of platelet activation by vWF Thromb Haemost. 2002;87(3):509-517.
12. Moro L, Reineri S, Piranda D, et al. Nongenomic effects of 17ß-estradiol in human platelets: potentiation of thrombin-induced aggregation through estrogen receptor beta and Src kinase. Blood. 2005;105(1):115-121.
13. 2 signaling pathway in shear-dependent platelet aggregation. Ann BiomedEng. 2004;32(9):1193-1201.
14. Consonni A, Cipolla L, Guidetti G, et al. Role and regulation of phosphatidylinositol 3-kinase ß in platelet integrin a2ß1 signaling. Blood. 2012; 119(3):847-856.
15. Koziak K, Kaczmarek E, Park SY, Fu Y, Avraham S, Avraham H. RAFTK/Pyk2 involvement in platelet activation is mediated by phosphoinositide 3-kinase. Br J Haematol. 2001;114(1):134-140.
16. Sayed MR, Sheid MP, Stevens CM, Duronio V Thrombin-stimulated phosphatidylinositol 3-kinase activity in platelets is associated with activation of Pyk2 tyrosine kinase: activation of both enzymes is aggregation independent. J Cell Physiol. 2000;183(3):314-320.
17. Osada M, Ohmori T, Yatomi Y, Satoh K, Hosogaya S, Ozaki Y Involvement of Hic-5 in platelet activation: integrin aIIbß3-dependent tyrosine phosphorylation and association with proline-rich tyrosine kinase 2. Biochem J. 2001;355(Pt3):691-697.
18. Ohmori T, Yatomi Y, Asazuma N, Satoh K, Ozaki Y Suppression of protein kinase C is associated with inhibition of Pyk2 tyrosine phosphorylation and enhancement of Pyk2 interaction with Src in thrombin-activated platelets. Thromb Res. 1999;93(6):291-298.
19. Okigaki M, Davis C, Falasca M, et al. Pyk2 regulates multiple signaling events crucial for macrophage morphology and migration. Proc Natl Acad Sci U S A. 2003;100(19):10740-10745.
20. Matsui A, Okigaki M, Amano K, et al. Central role of calcium-dependent tyrosine kinase Pyk2 in en-dothelial nitric oxide synthase-mediated angiogenic response and vascular function. Circulation. 2007;116(9):1041-1051.
21. Katsume A, Okigaki M, Matsui A, et al. Early Inflammatory reactions in atherosclerosis are induced by proline-rich tyrosine kinase/reactive oxygen species-mediated release of tumor necrosis factor-alpha and subsequent activation of the p21Cip1/Ets-1/p300 system. Arterioscler Thromb Vasc Biol. 2011;31(5):1084-1092.
22. Brecher G, Cronkite EP. Morphology and enumeration of human blood platelets. JAppl Physiol. 1950;3(6):365-377.
23. Momi S, Pitchford SC, Alberti PF, Minuz P, Del Soldato P, Gresele P. Nitroaspirin plus clopidogrel versus aspirin plus clopidogrel against platelet thromboembolism and intimal thickening in mice. Thromb Haemost. 2005;93(3):535-543.
24. Mancini F, Rigacci S, Berti A, Balduini C, Torti M. The low-molecular-weight phosphotyrosine phosphatase is a negative regulator of Fc7RIIA-mediated cell activation. Blood. 2007;110(6): 1871-1878.
25. Lova P, Campus F, Lombardi R, et al. Contribution of protease-activated receptors 1 and 4 and glycoprotein Ib-IX-V in the Gi-independent activation of platelet Rap1B by thrombin. J Biol Chem. 2004;279(24):25299-25306.
26. Momi S, Impagnatiello Guzzetta M, et al. NCX 6560, a nitric oxide-releasing derivative of atorva-statin, inhibits cholesterol biosynthesis and shows anti-inflammatory and anti-thrombotic properties. Eur J Pharmacol. 2007;570(1-3):115-124.
27. Momi S, Falcinelli E, Giannini S, et al. Loss of matrix metalloproteinase 2 in platelets reduces arterial thrombosis in vivo. J Exp Med. 2009; 206(11):2365-2379.
28. Momi S, Monopoli A, Alberti PF, et al. Nitric oxide enhances the anti-inflammatory and anti-atherogenic activity of atorvastatin in a mouse model of accelerated atherosclerosis. CardiovascRes. 2012;94(3): 428-438.
29. Leslie CC. Properties and regulation of cytosolic phospholipase A2. J Biol Chem. 1997;272(27): 16709-16712.
30. Hirabayashi T, Murayama T, Shimizu T. Regulatory mechanism and physiological role of cytoso-lic phospholipase A2. Biol Pharm Bull. 2004; 27(8):1168-1173.
31. Börsch-Haubold AG, Kramer RM, Watson SP. Cytosolic phospholipase A2 is phosphorylated in collagen-and thrombin-stimulated human platelets independent of protein kinase C and mitogen-activated protein kinase. J Biol Chem. 1995;270(43):25885-25892.
32. Buschbeck M, Ghomashchi F, Gelb MH, Watson SP, Börsch-Haubold AG. Stress stimuli increase calcium-induced arachidonic acid release through phosphorylation of cytosolic phos-pholipase A2. Biochem J. 1999;344(Pt2):359- 366.
33. Börsch-Haubold AG, Kramer RM, Watson SP. Phosphorylation and activation of cytosolic phos-pholipase A2 by 38-kDa mitogen-activated protein kinase in collagen-stimulated human platelets. Eur J Biochem. 1997;245(3):751-759.
34. Leoncini G, Bruzzese D, Signorello MG. Activation of p38 MAPKinase/cPLA2 pathway in homocysteine-treated platelets. J Thromb Hae-most. 2006;4(1):209-216.
35. Pandey P, Avraham S, Kumar S, et al. Activation of p38 mitogen-activated protein kinase by PYK2/related adhesion focal tyrosine kinase-dependent mechanism. J Biol Chem. 1999;274(15):10140-10144.
36. Tokiwa G, Dikic I, Lev S, Schlessinger J. Activation of Pyk2 by stress signals and coupling with JNK signaling pathway. Science. 1996; 273(5276):792-794.
37. Blaukat A, Ivankovic-Dikic I, Grönroos E, et al. Adaptor proteins Grb2 and Crk couple Pyk2 with activation of specific mitogen-activated protein kinase cascades. J Biol Chem. 1999;274(21): 14893-14901.
38. Dikic I, Tokiwa G, Lev S, Courtneidge SA, Schlessinger J. A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP ki-nase activation. Nature. 1996;383(6600):547-550.
39. Anand AR, Prasad A, Bradley RR, et al. HIV-1 gp120-induced migration of dendritic cells is regulated by a novel kinase cascade involving Pyk2, p38 MAP kinase, and LSP1. Blood. 2009; 114(17):3588-3600.
40. Kuliopulos A, Mohanlal R, Covic L. Effect of selective inhibition of p38MAP kinase pathway on platelet aggregation. Thromb Haemost. 2004; 92(6):1387-1393.
41. Lipinski CA, Loftus JC. Targeting Pyk2 for therapeutic intervention. Expert Opin Ther Targets. 2010;14(1):95-108.
42. Gresele P, Corona C, Alberti P, Nenci GG. Picota-mide protects mice from death in a pulmonary embolism model by a mechanism independent from thromboxane suppression. Thromb Hae-most. 1990;64(1):80-86.
43. Gresele P, Deckmyn H, Nenci GG, Vermylen J. Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in throm-botic disorders. Trends Pharmacol Sci. 1991; 12(4):158-163.
44. 2 syn-thase and cAMP phosphodiesterase. J Med Chem. 1992;35(4):620-628.
45. 2 synthase inhibitor, in a rat middle cerebral artery thrombosis model. Thromb Res. 1995;79(1): 95-107.
46. Takiguchi Y, Hirata Y, Wada K, Nakashima M. Arterial thrombosis model with photochemical reaction in guinea-pig and its property. Thromb Res. 1992;67(4):435-445.
47. Gresele P, Falcinelli E, Momi S. Potentiation and priming of platelet activation: a potential target for antiplatelet therapy. Trends Pharmacol Sci. 2008; 29(7):352-360.